shares of global blood therapeutics inc gbt were up 344 in premarket trading on thursday after bloomberg reported that the company is attracting takeover interest citing people familiar with the matter global blood therapeutics markets a treatment for sicklecell disease called oxbryta which generated 1947 million in revenue in 2021 the companys stock is up 159 this year while the sp 500 spx is down 128